Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 2(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04615949Phase 2Terminated

Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors

Role: lead

NCT06708299Phase 3Recruiting

CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)

Role: lead

NCT05494788Phase 2Completed

Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)

Role: lead

NCT05180240Phase 2Completed

Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis

Role: lead

All 4 trials loaded